Director, Biostatistics - Late Phase

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Requirements

• Ph.D. or M.S. in Statistics/Biostatistics
• A minimum of 8 years (for Ph.D.) and 12 years (for M.S.) of experience in the biotech/pharma industry as a statistician
• Hands-on experience in design and analysis of late-stage oncology trials
• Ability to work independently and within a team
• Solid knowledge in ICH and other regulatory requirements related to biostatistical activities and clinical trials
• Excellent verbal and written communication skills
• Good interpersonal and project management skills
• Proficiency in SAS and/or R

Benefits

• Competitive cash compensation
• Robust equity awards
• Strong benefits
• Significant learning and development opportunities